Ganglioside vaccines with emphasis on GM2 - PubMed (original) (raw)

Affiliations

• PMID: 9865678

Review

Ganglioside vaccines with emphasis on GM2

P Livingston. Semin Oncol. 1998 Dec.

Abstract

Gangliosides are neuraminic acid-containing glycosphingolipids that are anchored into the cell membrane lipid bilayer by lipophilic ceramide chains. They are overexpressed on tissues of neuroectodermal origin, and particularly in tumors such as melanomas, sarcomas, neuroblastomas, astrocytomas, and small cell lung cancers. Both active and passive immunotherapy trials have identified gangliosides as uniquely effective targets for antibody mediated melanoma immunotherapy. Induction of antibodies against GM2 by vaccination has correlated with an improved prognosis in American Joint Committee on Cancer (AJCC) stage III melanoma patients and vaccines containing GM2 chemically conjugated to keyhole limpet hemocyanin (KLH; GM2-KLH) plus the immunologic adjuvant QS-21 have proven to be consistently immunogenic. Phase III trials with this vaccine are ongoing in patients with melanoma in the United States, Canada, Europe, Australia, and New Zealand. GD2, fucosylated GMI, and GD3-KLH conjugates plus QS-21 are also consistently immunogenic, inducing IgM and IgG antibodies in the majority of patients. Polyvalent ganglioside-KLH conjugate plus QS-21 vaccines should be available in early 1999 for testing in phase II and III clinical trials.

PubMed Disclaimer

Similar articles

• Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21.
  Ragupathi G, Livingston PO, Hood C, Gathuru J, Krown SE, Chapman PB, Wolchok JD, Williams LJ, Oldfield RC, Hwu WJ. Ragupathi G, et al. Clin Cancer Res. 2003 Nov 1;9(14):5214-20. Clin Cancer Res. 2003. PMID: 14614001
• Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines.
  Livingston PO. Livingston PO. Immunol Rev. 1995 Jun;145:147-66. doi: 10.1111/j.1600-065x.1995.tb00080.x. Immunol Rev. 1995. PMID: 7590824 Review.
• GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21.
  Helling F, Zhang S, Shang A, Adluri S, Calves M, Koganty R, Longenecker BM, Yao TJ, Oettgen HF, Livingston PO. Helling F, et al. Cancer Res. 1995 Jul 1;55(13):2783-8. Cancer Res. 1995. PMID: 7796403 Clinical Trial.
• Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21.
  Ragupathi G, Meyers M, Adluri S, Howard L, Musselli C, Livingston PO. Ragupathi G, et al. Int J Cancer. 2000 Mar 1;85(5):659-66. doi: 10.1002/(sici)1097-0215(20000301)85:5<659::aid-ijc11>3.0.co;2-5. Int J Cancer. 2000. PMID: 10699946 Clinical Trial.
• Ganglioside conjugate vaccines. Immunotherapy against tumors of neuroectodermal origin.
  Helling F, Livingston PO. Helling F, et al. Mol Chem Neuropathol. 1994 Feb-Apr;21(2-3):299-309. doi: 10.1007/BF02815357. Mol Chem Neuropathol. 1994. PMID: 8086040 Review.

Cited by

• Vaccine and immune cell therapy in non-small cell lung cancer.
  Oliveres H, Caglevic C, Passiglia F, Taverna S, Smits E, Rolfo C. Oliveres H, et al. J Thorac Dis. 2018 May;10(Suppl 13):S1602-S1614. doi: 10.21037/jtd.2018.05.134. J Thorac Dis. 2018. PMID: 29951309 Free PMC article. Review.
• A four-marker signature of TNF-RII, TGF-α, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma.
  Tarhini AA, Lin Y, Yeku O, LaFramboise WA, Ashraf M, Sander C, Lee S, Kirkwood JM. Tarhini AA, et al. J Transl Med. 2014 Jan 23;12:19. doi: 10.1186/1479-5876-12-19. J Transl Med. 2014. PMID: 24457057 Free PMC article.
• Acute inflammatory neuropathy with monoclonal anti-GM2 IgM antibodies, IgM-κ paraprotein and additional autoimmune processes in association with a diffuse large B-cell non-Hodgkin's lymphoma.
  Milnik A, Roggenbuck D, Conrad K, Bartels C. Milnik A, et al. BMJ Case Rep. 2013 Jan 21;2013:bcr1120115087. doi: 10.1136/bcr-11-2011-5087. BMJ Case Rep. 2013. PMID: 23341581 Free PMC article.
• Adjuvant therapy: melanoma.
  Davar D, Tarhini A, Kirkwood JM. Davar D, et al. J Skin Cancer. 2011;2011:274382. doi: 10.1155/2011/274382. Epub 2011 Dec 19. J Skin Cancer. 2011. PMID: 22220281 Free PMC article.
• Immunologic mapping of glycomes: implications for cancer diagnosis and therapy.
  Zhou D, Levery SB, Hsu FF, Wang PG, Teneberg S, Almeida IC, Li Y, Xu H, Wang LX, Xia C, Ibrahim NK, Michael K. Zhou D, et al. Front Biosci (Schol Ed). 2011 Jun 1;3(4):1520-32. doi: 10.2741/242. Front Biosci (Schol Ed). 2011. PMID: 21622287 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Other Literature Sources

  • The Lens - Patent Citations

• Medical

  • MedlinePlus Health Information